Ask AI
ProCE Banner Activity

CodeBreaK 101 Cohort G: Sotorasib + Panitumumab and FOLFIRI in Previously Treated KRAS G12C–Mutated mCRC

Conference Coverage
Slideset

Long-term analysis from the phase Ib CodeBreaK 101 cohort G evaluating the combination of sotorasib plus panitumumab and FOLFIRI in patients with previously treated KRAS G12C–mutated mCRC showed that the combination demonstrated encouraging efficacy and safety and warranted further study in the ongoing phase III CodeBreaK 301.

Released: June 05, 2025

Expiration: December 04, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Daiichi Sankyo, Inc. and Genentech, a member of the Roche Group.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group